Orka Had Two Years Of Failure Before Its Viral Breakthrough - Forbes
4 weeks ago • Google News
Oruka Therapeutics, Inc. (ORKA)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 604.83M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
0
52W High
$ 31.13
52W Low
$ 5.49
Dividend Yield
0.00%
Beta
0.00
Technicals
50-Day MA
14.5238
200-Day MA
13.4895
52 Week High
31.13
52 Week Low
5.49
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indi.
Employees
28
Headquarters
Menlo Park, CA
CEO
Dr. Lawrence Otto Klein Ph.D.